SOT 62nd Annual Meeting and ToxExpo
LBG’s Sarah K. Herring, Ph.D. and Kyle V. Kappeler, Ph.D. will participate in critical conversations with thought leaders at the SOT 62nd Annual Meeting and ToxExpo.
This informative event, which brings together more than 5,000 toxicologists and those working in areas related to toxicology, takes place on March 19 – 23 in Nashville.
As attendees, Dr. Herring and Dr. Kappeler will have the opportunity to share their expertise and insight about the latest technology in the field.
“Nonclinical toxicologists are responsible for ensuring the safety of novel drugs, vaccines, and biologics to the best of their ability before human administration,” says Dr. Herring. “However, recent years have yielded several critical changes that directly impact traditional product development paradigms. The authorization of the new FDA Modernization Act, the shifting emphasis on regenerative medicine, and the increasing difficulties and costs associated with the acquisition and maintenance of large animal models traditionally used for safety evaluation now require ‘outside-of-the-box’ thinking.
“It is therefore critical that research scientists, industry toxicologists, pharmaceutical development professionals, and regulatory agencies engage in consistent dialogue regarding innovative changes that will help drive product development of life-saving human and animal pharmaceuticals forward for years to come.”
“The conference offers all levels of toxicologists/scientists the opportunity to attend key scientific sessions to learn about new advancements in the field of toxicology and to interact with thought leaders to discuss a variety of topics that could impact the future landscape of toxicological assessments,” says Dr. Kappeler. “Another important aspect of attending SOT is meeting new people from academy, regulatory agencies, chemical/biotechnology/pharmaceutical companies, vendors (CROs, consulting firms, service providers) to expand one’s network within the field of toxicology.”
As a Nonclinical Product Development Consultant at LBG, Dr. Herring provides customized, client-focused strategic and operational nonclinical support for a diverse portfolio of clientele developing various classifications of vaccines, prophylactics, and/or therapeutics. She previously performed the role of Study Director and Scientific Advisor in the toxicology group at Charles River Laboratories. In addition, Dr. Herring was responsible for independently conducting in-depth scientific reviews of study materials for the Toxicology, Pharmacokinetics, and Safety Pharmacology group with the goal of ensuring scientific accuracy and compliance with applicable regulations.
Dr. Kappeler has more than 10 years of subject matter expertise in preclinical toxicology and safety support for IND/NDA, Global Registration, Food Safety Assessment, Companion Animal, and Animal Rule submissions in accordance with FDA, OECD, U.S. EPA, ICH and/or EFSA guidelines. He possesses an expert understanding of non-GLP and GLP-compliant (21 CRF Part 58) preclinical program design and costing, protocol development, program management, study monitoring/execution, report generation, and SEND management.
